



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date:- May 29, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

BSE Script Code: 531599

NSE Symbol: FDC

Sub: Press Release on Q4 - FY 2024-25 and 12M - FY 2024-25 Results.

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended March 31, 2025.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

Varsharani Katre

Company Secretary & Compliance Officer

M No.: FCS-8948

CORPORATE OFFICE

: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE

: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176




FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

FDC Limited reports Q4FY25 results

Mumbai, 28th May 2025: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the fourth quarter ended 31st Mar 2025.



Consolidated Q4FY25 FDC and FY25 reported

Rs. in crores	Q4FY25	Q4FY24	YoY Grw %	FY25	FY24	YoY Grw %
Operating Revenue	492	462	6.5%	2,108	1,943	8.5%
EBITDA	54	56	-4.2%	325	339	-4.1%
EBITDA %	11.0%	12.2%		15.4%	17.4%	
PBT	53	65	-18.3%	357	396	-9.8%
PAT	39	46	-16.5%	267	305	-12.5%
EPS (Rs.)	2.38	2.84	-16.5%	16.39	18.58	-11.8%

Commenting on the results;

We're pleased to share that your Company crossed the ₹2,000 crore revenue mark in FY25, growing 8.5% to reach ₹2,108 crore. This milestone reflects the continued strength of our India Formulations business, which contributed 84% of sales and growing with 14.4% YoY, and strong momentum in our API segment, which grew 21.1% YoY. Export Formulation business however reported decline of 25.6% YoY primarily due to lower sales in US market and few of the ROW markets. Lower sales in US market were majorly due to regulatory issues. The regulatory issues of US market have now been addressed, and management believe the business should be back in its normal flow in the coming financial year.



CORPORATE OFFICE

: 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102, INDIA
Tel.: +91-22-3071 9100 / 399 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2678 6393 / 8123 / 1912
E-mail: fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE

: B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176

Profitability during the year was impacted primarily due to drop in the Export formulation business, reduction in price of Electral due to NLEM price revision announcement during Q1FY25, and higher employee costs in view of moderate expansion in field force in certain clusters of India market.

Business-wise Sales Performance

₹ Cr	Q4FY25	YoY Grw %	FY25	YoY Grw %
Net Sales	492	6.5%	2,108	8.5%
India Formulations	415	16.7%	1,773	14.4%
US Formulations	10	-74.4%	63	-57.5%
Emerging Markets	36	-4.2%	155	7.6%
API Sales	30	11.5%	112	21.1%

India Market:

The sale of branded formulations in India for Q4FY25 was Rs. 415 crores, with a growth of 16.7% on YoY and up by 7.0% over QoQ. For FY25, sales were at Rs. 1,773 crores, a healthy growth of 14.4% over FY24. Overall sales in the Indian market accounted for 85% of total consolidated sales for the quarter and 84% for FY25.

As per secondary sales data by IQVIA for the quarter ended Mar 31, 2025, the Company delivered YoY growth of 15.5% compared to the Indian Pharmaceutical Market (IPM) growth of 7.3% YoY. Electral has moved up to 15th rank in IPM in MAT Mar'25 as compared to 22nd in the same period last year.

Further, the company was the 2nd fastest growing company as per MAT Mar'25 among the Top 25 companies, supported majorly by flagship brand Electral, Zifi and Enerzal.

Export Formulations Market:

Formulation Sales in the Export market were Rs. 46 crores in Q4FY25, down by 39.2% over YoY and lower by 3.6% over QoQ and accounted for 9% of total consolidated sales. FY25 Sales were Rs. 218 crores, down by 25.6% over FY24.

Regulatory issues which contributed to drop in US formulation business have been addresses in later part of Q4FY25 and management believes the growth momentum in Export formulation business to be back in the coming financial year.



API Business:

API business showed good traction of growth momentum with sales of Rs. 30 crores in Q4FY25, up by 11.5% over YoY and up by 7.4% over QoQ and accounted for 6% of total consolidated sales. During FY25, the API business grew by 21%, registering sales of Rs. 112crs.

ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

